Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study

Abstract Background In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus disease 2019 (COVID-19) due to Omicron BA.2. Methods A m...

Full description

Bibliographic Details

Published in:	BMC Research Notes
Main Authors:	Carson K. L. Lo, Calvin K. F. Lo, Adam S. Komorowski, Victor Leung, Nancy Matic, Susan McKenna, Santiago Perez-Patrigeon, Prameet M. Sheth, Christopher F. Lowe, Zain Chagla, Anthony D. Bai
Format:	Article
Language:	English
Published:	BMC 2024-01-01
Subjects:	Sotrovimab SARS-CoV-2 COVID-19 COVID-19 drug treatment Omicron BA.2 subvariant
Online Access:	https://doi.org/10.1186/s13104-024-06695-x